MEMORANDUM

TO: Federally Qualified Health Centers / Rural Health Centers (FQHCs/RHCs)
    QUEST Integration (QI) Health Plans

FROM: Judy Mohr Peterson, PhD
      Med-QUEST Division Administrator

SUBJECT: COVID-19 MONOCLONAL ANTIBODY TREATMENT – FQHC/RHC
         REIMBURSEMENT FOR ADMINISTRATION

This memo replaces QI-2126 and FFS 21-11 issued on September 30, 2021. The administration
fee allowance and effective dates were changed to reflect and align with Hawaii adjusted
Medicare rates.

This memorandum is being issued as Federally Qualified Health Centers/Rural Health Centers
(FQHCs/RHCs) are now one of the providers who are able to receive reimbursement for the
administration of COVID-19 Monoclonal Antibody products.

In our assessment, the cost to provide monoclonal treatments is not currently included in
FQHC/RHC Prospective Payment System (PPS) rate calculation. Therefore, FQHCs/RHCs that
administer monoclonal infusion therapy or by injection are to be reimbursed at the fee-for-
service (FFS) rather than their PPS rate.

The administration of monoclonal antibodies must be in accordance with current FDA guidelines.
Details on reimbursement of the administration fee in terms of codes, rates, and effective dates
are outlined below. The FQHC/RHC should bill only the FFS administration fee for the monoclonal

AN EQUAL OPPORTUNITY AGENCY
therapy and will not be eligible for PPS on the same day unless it is for an issue unrelated to the administration of the monoclonal therapy.

<table>
<thead>
<tr>
<th>HCPCS Code</th>
<th>HCPCS Short Descriptor</th>
<th>Administration Fee Allowance</th>
<th>Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>M0243</td>
<td>Casirivi and imdevi inj</td>
<td>$ 505.74</td>
<td>05/06/21</td>
</tr>
<tr>
<td>M0244</td>
<td>Casirivi and imdevi inj hm</td>
<td>$ 843.38</td>
<td>05/06/21</td>
</tr>
<tr>
<td>M0240</td>
<td>Casirivi and imdev repeat</td>
<td>$ 505.74</td>
<td>05/06/21</td>
</tr>
<tr>
<td>M0241</td>
<td>Casirivi and imdev repeat hm</td>
<td>$ 843.38</td>
<td>05/06/21</td>
</tr>
<tr>
<td>M0245</td>
<td>Bamlan and etesev infusion</td>
<td>$ 505.74</td>
<td>05/06/21</td>
</tr>
<tr>
<td>M0246</td>
<td>Bamlan and etesev infusion hm</td>
<td>$ 843.38</td>
<td>05/06/21</td>
</tr>
</tbody>
</table>

This policy supports MQD’s continued COVID-19 public health emergency response and recovery efforts to provide timely care with improved outcomes, increase access to care in our beneficiary’s communities, and decrease hospitalization.

Should you have questions please contact Leslie K. Tawata, Clinical Standards Office Administrator at ltawata@dhs.hawaii.gov.

References:
1) FDA: Drugs. https://www.fda.gov/drugs